PVLA
NASDAQ · Biotechnology
Palvella Therapeutics Inc
$157.77
+2.84 (+1.83%)
Open$159.00
Previous Close$154.93
Day High$160.21
Day Low$156.09
52W High$161.38
52W Low$37.33
Volume—
Avg Volume165.2K
Market Cap2.27B
P/E Ratio—
EPS$-4.82
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
-66.5% upside
Current
$157.77
$157.77
Target
$52.81
$52.81
$42.56
$52.81 avg
$76.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 613.91M | 541.18M | 158.95M |
| Net Income | -123,095,577 | -97,660,454 | 26.26M |
| Profit Margin | -57.3% | -54.5% | 16.5% |
| EBITDA | -101,372,638 | -84,894,222 | 46.23M |
| Free Cash Flow | — | — | 10.92M |
| Rev Growth | +13.4% | +13.4% | +20.5% |
| Debt/Equity | 0.63 | 0.63 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |